MEI Pharma's Pracinostat gets orphan drug status from FDA

CEO Daniel Gold: "We are very pleased to receive this orphan drug designation ... AML is a particularly devastating cancer for which there are currently few broadly effective treatments. Through development of Pracinostat, we hope to address this significant unmet medical need."

No trades premarket, but MEIP gained 23.8% last night in AH action.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs